Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma.
Xiong J, Cui BW, Wang N, Dai YT, Zhang H, Wang CF, Zhong HJ, Cheng S, Ou-Yang BS, Hu Y, Zhang X, Xu B, Qian WB, Tao R, Yan F, Hu JD, Hou M, Ma XJ, Wang X, Liu YH, Zhu ZM, Huang XB, Liu L, Wu CY, Huang L, Shen YF, Huang RB, Xu JY, Wang C, Wu DP, Yu L, Li JF, Xu PP, Wang L, Huang JY, Chen SJ, Zhao WL. Xiong J, et al. Among authors: qian wb. Cancer Cell. 2020 Mar 16;37(3):403-419.e6. doi: 10.1016/j.ccell.2020.02.005. Cancer Cell. 2020. PMID: 32183952 Free article.
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.
Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J, Jin C, Zou L, Qiu L, Li W, Yang J, Hou M, Zeng S, Zhang Q, Hu J, Zhou H, Xiong Y, Liu P. Shi Y, et al. Lancet Haematol. 2019 Jan;6(1):e12-e19. doi: 10.1016/S2352-3026(18)30192-3. Lancet Haematol. 2019. PMID: 30612710 Clinical Trial.
Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy.
Mei H, Chen F, Han Y, Hou M, Huang H, Huang X, Li Y, Liang A, Liu Q, Niu T, Peng J, Qian W, Song Y, Wang J, Wang Y, Wu D, Xu K, Yang L, Yang R, Zhang L, Zhang L, Zhang X, Zhang X, Zhao W, Han W, Hu Y. Mei H, et al. Chin Med J (Engl). 2022 Jul 20;135(14):1639-1641. doi: 10.1097/CM9.0000000000002288. Chin Med J (Engl). 2022. PMID: 35984103 Free PMC article. No abstract available.
Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study.
Zhong H, Cheng S, Zhang X, Xu B, Chen J, Jiang X, Xiong J, Hu Y, Cui G, Wei J, Qian W, Huang X, Hou M, Yan F, Wang X, Song Y, Hu J, Liu Y, Ma X, Li F, Wu C, Chen J, Yu L, Bai O, Xu J, Zhu Z, Liu L, Zhou X, Huang L, Tong Y, Niu T, Wu D, Zhang H, Wang C, Ouyang B, Yi H, Song Q, Cai G, Li B, Liu J, Li Z, Xiao R, Wang L, Jiang Y, Liu Y, Zheng X, Xu P, Huang H, Wang L, Chen S, Zhao W. Zhong H, et al. Innovation (Camb). 2023 Apr 13;4(3):100426. doi: 10.1016/j.xinn.2023.100426. eCollection 2023 May 15. Innovation (Camb). 2023. PMID: 37181228 Free PMC article.
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.
Qin Y, Song Y, Wang D, Bai O, Feng J, Sun X, Qiu L, Yang J, Yang Y, Wang Z, Hu J, Wang H, Su H, Jin Z, Qian W, Jin C, Zhang M, Yu D, Liu L, Chen G, Li Y, Sun T, Jin J, Bao H, Du X, Zhou H, Fu G, Shi Y. Qin Y, et al. BMC Cancer. 2024 Jan 24;24(1):124. doi: 10.1186/s12885-024-11876-9. BMC Cancer. 2024. PMID: 38267866 Free PMC article. Clinical Trial.
267 results